Brasília – Some medicines already incorporated into Brazil’s public health system (SUS) take up to 11 years to reach patients, according to a report by O Estado de S. Paulo. Experts warn that such delays can represent “the difference between cure and death,” particularly for those with cancer or rare diseases.

The study, based on data from Interfarma and the Oncoguia Institute, highlights that the problem lies not in the approval process itself but in the implementation and distribution of treatments. While Conitec recommends the incorporation of new drugs, the actual delivery often faces regulatory bottlenecks, budget constraints, and logistical failures across states and municipalities.

The report also points to weaknesses in supply chain planning and monitoring, resulting in long waits for patients even after government approval. The situation underscores the persistent gap between policy decisions and access to innovative therapies within the SUS.

Source: O Estado de S. Paulo

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com